复星医药(02196.HK) 公布,控股子公司星浩澎博近日收到国家药品监督管理局同意XH-S004片用于治疗慢性阻塞性肺疾病的临床试验批准。XH-S004为集团自主研发的小分子口服DPP-1抑制剂,拟用于治疗慢性阻塞性肺疾病、非囊性纤维化支气管扩张症等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-06 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.